{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-034907","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.427653+00:00","generated_at":"2026-05-30T00:51:46.843307+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Talphera Q3 net loss widens to $3.4M; NEPHRO CRRT study enrollment underway","bullets":["Net loss $3.4M ($0.13/share) vs $1.4M ($0.08) in Q3 2023; cash and investments $11.1M.","Five clinical sites screening for NEPHRO CRRT study; two more expected in Q4; study completion anticipated in 2025.","Combined R&D and SG&A expenses $3.7M, up from $3.4M, driven by NEPHRO study costs.","DSUVIA divestment classified as discontinued operations; no related expenses in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-034907","json":"https://secwatch.observer/filing/0001437749-24-034907.json","markdown":"https://secwatch.observer/filing/0001437749-24-034907.md","text":"https://secwatch.observer/filing/0001437749-24-034907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924034907/0001437749-24-034907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924034907/acrx20241112_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:51:46.843307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}